科笛折让12%配股筹2.4亿港元

Group 1 - The company plans to issue 28.904 million new shares, representing approximately 8.3% of the enlarged share capital [1] - The subscription price is set at HKD 8.4 per share, which is a discount of 12.04% compared to the closing price of HKD 9.55 yesterday [1] - The total fundraising amount is expected to be HKD 243 million [1] Group 2 - Approximately 45% of the net proceeds from the placement will be allocated to preclinical research and clinical trials for localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - About 10% of the proceeds will be utilized for working capital and other general corporate purposes [1]